Afatinib tablets are targeted anticancer medicines used in the treatment of certain types of non-small cell lung cancer (NSCLC), particularly cancers associated with specific EGFR (epidermal growth factor receptor) mutations. Afatinib belongs to the tyrosine kinase inhibitor (TKI) class and works by blocking signaling pathways involved in cancer-cell growth.
In India, Afatinib has been approved in tablet strengths including 20 mg, 30 mg, 40 mg and 50 mg, with regulatory documentation covering its use in locally advanced or metastatic NSCLC with EGFR mutations.
What Is Afatinib?
Afatinib is an oral targeted therapy that inhibits members of the ErbB receptor family, including EGFR (ErbB1) and HER2 (ErbB2). By interfering with these signaling pathways, Afatinib can help reduce signals that promote the growth and multiplication of certain cancer cells.
It is generally used when the patient's cancer has a molecular profile for which Afatinib is an appropriate treatment option. Selection of targeted therapy should be made by a qualified oncology professional based on the patient's diagnosis and test results.
Afatinib Tablets Composition
Afatinib tablets contain Afatinib as the active pharmaceutical ingredient (API). The medicine is available in different strengths, including:
- Afatinib 20 mg tablets
- Afatinib 30 mg tablets
- Afatinib 40 mg tablets
- Afatinib 50 mg tablets in certain approved products
CDSCO documentation specifically records Afatinib tablet strengths of 20 mg, 30 mg, 40 mg and 50 mg.
The exact inactive ingredients, tablet coating and excipient composition can vary between manufacturers and brands. Pharmaceutical buyers should therefore check the manufacturer's product specification, package insert and approved product documentation before procurement.
Afatinib Tablets Uses
The primary therapeutic use of Afatinib is in certain patients with non-small cell lung cancer (NSCLC).
Indian regulatory documentation has described Afatinib for the treatment of locally advanced or metastatic NSCLC with EGFR mutations.
Afatinib has also been documented for certain patients with squamous NSCLC progressing on or after platinum-based chemotherapy, subject to the applicable regulatory indication and prescribing requirements.
Because NSCLC is a complex disease with different molecular characteristics, Afatinib is not appropriate for every lung-cancer patient. EGFR mutation status and other clinical factors are important when determining whether this treatment is suitable.
How Does Afatinib Work?
Afatinib is an irreversible ErbB family tyrosine kinase inhibitor. It binds to and inhibits signaling from receptor tyrosine kinases in the ErbB family, including EGFR and HER2.
These receptors can contribute to pathways involved in cancer-cell proliferation and survival. Blocking their signaling can interfere with the growth of tumors that depend on these pathways.
CDSCO scientific documentation describes Afatinib as a selective and potent irreversible inhibitor of ErbB-family TKI receptors.
Afatinib 20mg, 30mg and 40mg Tablets
Different Afatinib strengths are available to accommodate prescribing requirements and dose adjustments.
Afatinib 20 mg tablets may be used when a lower dose is prescribed.
Afatinib 30 mg tablets provide an intermediate strength and may be relevant where dose adjustment is required.
Afatinib 40 mg tablets are another commonly referenced strength in Afatinib product information and regulatory records.
The appropriate strength and dosing schedule should always be determined by the treating oncologist. Patients should not change the Afatinib dose, stop treatment or switch strengths without medical supervision.
Important Safety Information
Afatinib can cause adverse reactions and requires appropriate medical monitoring. Commonly reported adverse reactions include diarrhea, rash or acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting and itching.
Important warnings associated with Afatinib include potentially serious skin reactions, interstitial lung disease, liver toxicity, gastrointestinal complications and eye-related adverse effects.
Patients should report unusual or severe symptoms promptly to their healthcare professional. The complete prescribing information should be reviewed before treatment.
Afatinib Tablets for Pharmaceutical Buyers in India
For pharmaceutical distributors, hospitals, oncology-focused healthcare organizations and other authorized buyers, procurement should include verification of the manufacturer, strength, batch information, expiry date, packaging, storage requirements and applicable regulatory documentation.
Global Pharma Trade can provide information regarding Afatinib tablets 20 mg, 30 mg and 40 mg for eligible pharmaceutical buyers seeking supply from India. Availability, packaging and commercial terms can vary according to the product and order requirements.
Buyers interested in bulk procurement can contact the supplier with the required strength, quantity, destination and documentation requirements to request a quotation.
Frequently Asked Questions About Afatinib Tablets
What are Afatinib tablets used for?
Afatinib is used for certain forms of NSCLC, including NSCLC associated with specific EGFR mutations. The appropriate indication depends on the patient's clinical and molecular characteristics.
What strengths of Afatinib tablets are available?
Afatinib tablets are available in strengths including 20 mg, 30 mg and 40 mg, with 50 mg also appearing in Indian regulatory documentation for certain products.
Is Afatinib a chemotherapy medicine?
Afatinib is a targeted tyrosine kinase inhibitor, rather than a conventional cytotoxic chemotherapy drug. It targets specific signaling pathways associated with cancer-cell growth.
Who should determine the Afatinib dose?
The treating oncologist should determine the appropriate Afatinib dose based on the patient's cancer characteristics, overall clinical condition, response and tolerability.
Can Afatinib tablets be purchased in bulk in India?
Authorized pharmaceutical buyers may enquire about bulk supply subject to product availability, applicable regulations and supplier requirements. Buyers should provide the required strength and quantity when requesting a quotation.
Conclusion
Afatinib tablets are an important targeted therapy used in selected patients with non-small cell lung cancer, particularly where relevant EGFR mutations are present. Afatinib is available in multiple strengths, including 20 mg, 30 mg and 40 mg, allowing healthcare professionals to select or adjust treatment according to clinical requirements.
For Indian pharmaceutical distributors, hospitals and authorized healthcare buyers looking for Afatinib tablets from India, checking product strength, manufacturer documentation, packaging, batch details and applicable regulatory requirements is an important part of the procurement process.
Global Pharma Trade supports pharmaceutical buyers seeking information and supply options for Afatinib tablets. Contact the team with your required strength and quantity to discuss availability and request a quotation.
